Genentech, Inc.
NEWS
AbbVie’s Allergan Aesthetics announced it was buying Soliton in a deal worth about $550 million. Now, the Federal Trade Commission has requested additional information about the deal.
As the Delta variant rages on and COVID-19 vaccines move closer to receiving full regulatory approval, many companies across the U.S. and abroad are beginning to mandate their employees get the jab or get the boot.
The clinical study compared Enhertu to Kadcyla in HER2+ metastatic breast cancer patients who previously received trastuzumab.
As the spread of the Delta variant exacerbates the COVID-19 pandemic, companies are increasingly moving toward requiring staffers to be vaccinated. Here’s a look at those stories and more.
It was another busy week for clinical trial updates. Here’s a look at some including Mesoblast Limited, CytoDyn, Magenta Therapeutics and more.
Genentech announced that the FDA has green-lit the Venclexta classification and azicitidine combination as a Breakthrough Therapy Drug.
Genentech’s Hemlibra showed no new safety signals and continued to deliver consistent bleeding control in the final analysis of a long-term, late-stage hemophilia A study.
The two were charged with conspiracy to commit trade secret theft and wire fraud, international money laundering and obstruction of justice.
Roche had a big week, scoring wins but also stepping away from its gene therapy partnership with 4D Molecular Therapeutics.
JOBS
IN THE PRESS